Mikobakterilerde İlaç Direncinin Belirlenmesinde Kullanılan Moleküler Testler
Referanslar
World Health Organization. Global Tuberculosis Report 2025. Geneva, Switzerland: World Health Organization; 2025.
The Joint United Nations Programme on HIV/AIDS. Global AIDS update 2016 (UNAIDS, 2016).
Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLoS One. 2014;9(1):e82235. Published 2014 Jan 8. doi:10.1371/journal.pone.0082235
World Health Organization. The End TB Strategy. Geneva, Switzerland: World Health Organization; 2015.
Farhat M, Cox H, Ghanem M, et al. Drug-resistant tuberculosis: a persistent global health concern. Nat Rev Microbiol. 2024;22(10):617-635. doi:10.1038/s41579-024-01025-1
Dheda K, Mirzayev F, Cirillo DM, et al. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024;10(1):22. Published 2024 Mar 24. doi:10.1038/s41572-024-00504-2
Domínguez J, Boeree MJ, Cambau E, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023;23(4):e122-e137. doi:10.1016/S1473-3099(22)00875-1
Naidoo K, Perumal R, Ngema SL, Shunmugam L, Somboro AM. Rapid Diagnosis of Drug-Resistant Tuberculosis-Opportunities and Challenges. Pathogens. 2023;13(1):27. Published 2023 Dec 27. doi:10.3390/pathogens13010027
World Health Organization. WHO consolidated guidelines on tuberculosis: Module 3: Rapid diagnostics for tuberculosis detection. Geneva, Switzerland: World Health Organization; 2025.
World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment and Care. Geneva, Switzerland: World Health Organization; 2025. https://www.who.int/publications/i/item/9789240107243
Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother. 2018;73(5):1138-1151. doi:10.1093/jac/dkx506
Andre E, Goeminne L, Cabibbe A, et al. Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clin Microbiol Infect. 2017;23(3):167-172. doi:10.1016/j.cmi.2016.09.006
Andre E, Goeminne L, Colmant A, Beckert P, Niemann S, Delmee M. Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis,a rifampicin-resistance-conferring mutation undetected by commercial assays. Clin Microbiol Infect. 2017 Apr;23(4):267.e5-267.e7. doi: 10.1016/j.cmi.2016.12.009.
Ei PW, Htwe MM, Nyunt MH, Mon AS, Myint Z, Nyunt WW, Win SM, Aung S, Thwe WM, Aung WW. Detection of I491F and V170F rpoB mutations associated with misdiagnosis of rifampicin resistance among patients with drug-susceptible tuberculosis treatment failure, Myanmar, 2022. J Glob Antimicrob Resist. 2025 Mar;41:169-172. doi: 10.1016/j.jgar.2024.12.026.
Soidah S, Subroto T, Faizal I, Yusuf M. Beyond Hotspot Mutations: Diagnostic Relevance of High Frequency, Low Frequency, and Disputed rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis. Pathogens. 2025;15(1):16. Published 2025 Dec 22. doi:10.3390/pathogens15010016
World Health Organization. Global Tuberculosis Report 2020. World Health Organization; 2020.
Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis. 1996;173(1):196-202. doi:10.1093/infdis/173.1.196
Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev. 1995;8(4):496-514. doi:10.1128/CMR.8.4.496
Rajendran A, Palaniyandi K. Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update. Curr Microbiol. 2022;79(11):348. Published 2022 Oct 8. doi:10.1007/s00284-022-03032-y
Ramirez-Busby SM, Valafar F. Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2015;59(9):5267-5277. doi:10.1128/AAC.00204-15
Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect. 2013;2(6):e34. doi:10.1038/emi.2013.38
Miotto P, Cabibbe AM, Feuerriegel S, et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. mBio. 2014;5(5):e01819-14. Published 2014 Oct 21. doi:10.1128/mBio.01819-14
Palomino JC, Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel) 2014; 3: 317–40.
Lingaraju S, Rigouts L, Gupta A, et al. Geographic Differences in the Contribution of ubiA Mutations to High-Level Ethambutol Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60(7):4101-4105. Published 2016 Jun 20. doi:10.1128/AAC.03002-15
Liu J, Shi W, Zhang S, Hao X, Maslov DA, Shur KV, Bekker OB, Danilenko VN and Zhang Y (2019) Mutations in Efflux Pump Rv1258c (Tap) Cause Resistance to Pyrazinamide, Isoniazid, and Streptomycin in M. tuberculosis. Front. Microbiol. 10:216. doi: 10.3389/fmicb.2019.00216
Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005-1015. doi:10.1056/NEJMoa0907847
Yu X, Huang H. Xpert-Ultra for diagnosing asymptomatic tuberculosis. Lancet Infect Dis. 2026;26(2):120-122. doi:10.1016/S1473-3099(25)00563-8
Mishra H, Reeve BWP, Palmer Z, et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. Lancet Respir Med. 2020;8(4):368-382. doi:10.1016/S2213-2600(19)30370-4
Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76-84. doi:10.1016/S1473-3099(17)30691-6
Theron G, Venter R, Calligaro G, et al. Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?. Clin Infect Dis. 2016;62(8):995-1001. doi:10.1093/cid/civ1223
Lin WH, Lee WT, Tsai HY, Jou R. Disputed rpoB Mutations in Mycobacterium tuberculosis and Tuberculosis Treatment Outcomes. Antimicrob Agents Chemother. 2021;65(7):e0157320. doi:10.1128/AAC.01573-20
Nikam C, Kazi M, Nair C, et al. Evaluation of the Indian TrueNAT micro RT-PCR device with GeneXpert for case detection of pulmonary tuberculosis. Int J Mycobacteriol. 2014;3(3):205-210. doi:10.1016/j.ijmyco.2014.04.003
Ngangue YR, Mbuli C, Neh A, et al. Diagnostic Accuracy of the Truenat MTB Plus Assay and Comparison with the Xpert MTB/RIF Assay to Detect Tuberculosis among Hospital Outpatients in Cameroon. J Clin Microbiol. 2022;60(8):e0015522. doi:10.1128/jcm.00155-22
Hofmann-Thiel S, Molodtsov N, Antonenka U, Hoffmann H. Evaluation of the Abbott RealTime MTB and RealTime MTB INH/RIF Assays for Direct Detection of Mycobacterium tuberculosis Complex and Resistance Markers in Respiratory and Extrapulmonary Specimens. J Clin Microbiol. 2016;54(12):3022-3027. doi:10.1128/JCM.01144-16
Bogiel T, Dolska E, Zimna M, et al. The Usefulness of the BD MAX MDR-TB Molecular Test in the Rapid Diagnosis of Multidrug-Resistant Tuberculosis. Pathogens. 2025;14(6):602. Published 2025 Jun 19. doi:10.3390/pathogens14060602
Hsueh SC, Chen CL, Lin CR, et al. Evaluation of the Roche cobas MTB and MTB-RIF/INH for detecting Mycobacterium tuberculosis complex and resistance to isoniazid and rifampicin: A prospective, multicenter diagnostic accuracy study. Int J Antimicrob Agents. 2025;66(6):107605. doi:10.1016/j.ijantimicag.2025.107605
FluoroType® MTB: the direct detection test for innovative labs [website]. Massachusetts: Bruker- Hain Diagnostics; 2019 (https://www.hain-lifescience.de/en/products/microbiology/mycobacteria/ tuberculosis/fluorotype-mtb.html).
Hain Lifescience GmbH. FluoroType® MTBDR VER 2.0: Instructions for Use. IFU-628-07. Hain Lifescience GmbH; 2021. Accessed September 3, 2026. https://www.hain-lifescience.de/include_datei/kundenmodule/packungsbeilage/download.php?id=3984
Sethi S, Sharma S, Aggarwal AN, Dhatwalia SK, Rana R, Yadav R. Xpert MTB/XDR assay: rapid TB drug resistance detection. Infection. 2024;52(6):2207-2212. doi:10.1007/s15010-024-02260-7
Hain Lifescience GmbH. GenoType MTBDRplus VER 2.0: Instructions for Use. IFU-304A-06. Hain Lifescience GmbH; 2015. https://www.hain-lifescience.de/include_datei/kundenmodule/packungsbeilage/download.php?id=936
World Health Organization. Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for laboratory staff and clinicians. Geneva, Switzerland: World Health Organization; 2018. Accessed February 20, 2026.
Driesen M, Kondo Y, de Jong BC, Torrea G, Asnong S, Desmaretz C, Mostofa KSM,Tahseen S, Whitfield MG, Cirillo DM, Miotto P, Cabibbe AM, Rigouts L. Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment. Clin Microbiol Infect. 2018 Jan;24(1):60-64.doi: 10.1016/j.cmi.2017.05.026.
Willby MJ, Wijkander M, Havumaki J, et al. Detection of Mycobacterium tuberculosis pncA Mutations by the Nipro Genoscholar PZA-TB II Assay Compared to Conventional Sequencing. Antimicrob Agents Chemother. 2017;62(1):e01871-17. Published 2017 Dec 21. doi:10.1128/AAC.01871-17
Nipro Corporation. Genoscholar™ PZA-TB II: TB drug resistance detection diagnostic. Osaka, Japan: Nipro Corporation.
World Health Organization. Catalogue of Mutations in Mycobacterium tuberculosis Complex and Their Association With Drug Resistance. 2nd ed. World Health Organization; 2023.
Meehan CJ, Goig GA, Kohl TA, et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol. 2019;17(9):533-545. doi:10.1038/s41579-019-0214-5
Ronaghi M. Pyrosequencing sheds light on DNA sequencing. Genome Res. 2001;11(1):3-11. doi:10.1101/gr.11.1.3
Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, Hoffner SE. Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology. J Clin Microbiol. 2006;44(6):1925-1929. doi:10.1128/JCM.02210-05
Schwab TC, Perrig L, Göller PC, et al. Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2024;24(10):1162-1176. doi:10.1016/S1473-3099(24)00263-9
Vīksna A, Sadovska D, Berge I, et al. Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia. BMC Infect Dis. 2023;23(1):638. Published 2023 Sep 28. doi:10.1186/s12879-023-08629-7
Alonso M, Palacios JJ, Herranz M, et al. Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category. J Clin Microbiol. 2011;49(7):2688-2690. doi:10.1128/JCM.00659-11
Soidah S, Subroto T, Faizal I, Yusuf M. Beyond Hotspot Mutations: Diagnostic Relevance of High Frequency, Low Frequency, and Disputed rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis. Pathogens. 2025;15(1):16. Published 2025 Dec 22. doi:10.3390/pathogens15010016
Abanda NN, Djieugoué JY, Khadka VS, et al. Absence of hybridization with the wild-type and mutant rpoB probes in the Genotype MTBDRplus assay detects 'disputed' rifampicin mutations. Clin Microbiol Infect. 2018;24(7):781.e1-781.e3. doi:10.1016/j.cmi.2017.11.021
Van Deun A, Aung KJ, Hossain A, et al. Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. Int J Tuberc Lung Dis. 2015;19(2):185-190. doi:10.5588/ijtld.14.0651
Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019;17(8):479-496. doi:10.1038/s41579-019-0218-1
Ye M, Yuan W, Molaeipour L, Azizian K, Ahmadi A, Kouhsari E. Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2021;20(1):73. Published 2021 Oct 13. doi:10.1186/s12941-021-00478-z
World Health Organization. Line Probe Assays for Detection of Drug-Resistant Tuberculosis: Interpretation and Reporting Manual for Laboratory Staff and Clinicians. World Health Organization; 2022.
Koh WJ. Nontuberculous Mycobacteria-Overview. Microbiol Spectr. 2017;5(1):10.1128/microbiolspec.tnmi7-0024-2016. doi:10.1128/microbiolspec.TNMI7-0024-2016
Cao Yao JC, Navas Méndez J, Tórtola Fernández MT. Analysis of Phenotypic and Genotypic Susceptibility to Clarithromycin and Amikacin of Mycobacterium abscessus Complex Strains Isolated from Cystic Fibrosis Patients. Microorganisms. 2023;11(12):2897. Published 2023 Nov 30. doi:10.3390/microorganisms11122897
Sirgel FA, Tait M, Warren RM, et al. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist. 2012;18(2):193-197. doi:10.1089/mdr.2011.0063
Kim SY, Jhun BW, Moon SM, et al. Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates. Antimicrob Agents Chemother. 2018;62(9):e00527-18. Published 2018 Aug 27. doi:10.1128/AAC.00527-18
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535. Published 2020 Jul 7. doi:10.1183/13993003.00535-2020
Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012;25(3):545-582. doi:10.1128/CMR.05030-11
Solanki P, Lipman M, McHugh TD, Satta G. Whole genome sequencing and prediction of antimicrobial susceptibilities in non-tuberculous mycobacteria. Front Microbiol. 2022;13:1044515. Published 2022 Nov 29. doi:10.3389/fmicb.2022.1044515
Walzl G, McNerney R, du Plessis N, et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis. 2018;18(7):e199-e210. doi:10.1016/S1473-3099(18)30111-7